| Heading: |
Drugs: Licensing |
| Question ID: |
1807387 |
| UIN: |
55820 |
| House: |
Commons |
| Date tabled: |
2025-05-30 |
| Asking Member ID: |
5300 |
| Asking Member display name: |
Kevin McKenna
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Kevin McKenna
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure the timely approval of high-tariff drugs for use in (a) specialised commissioning and (b) repurposed treatments. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-06 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
To market a medicine in the United Kingdom, a company must secure a marketing authorisation or ‘licence’ from the Medicines and Healthcare Products Regulatory Agency. Newly-licensed medicines, including licence extensions for existing medicines, are appra... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |